Disseminated Enteroviral Infection Associated with Obinutuzumab

Research output: Contribution to journalArticleOther

Abstract

Two cases of disseminated enteroviral infection occurred in patients who received the CD20 monoclonal antibody obinutuzumab. Clinical features included hepatitis, edema, and a dermatomyositis-like syndrome. These manifestations may be unfamiliar to clinicians and are possibly responsive to intravenous immunoglobulin. Clinicians should remain vigilant for enteroviral infections in patients receiving obinutuzumab.
Original languageEnglish
Pages (from-to)1661 - 1663
Number of pages3
JournalEmerging infectious diseases
Volume21
Issue number9
DOIs
Publication statusPublished - 2015

Cite this

@article{4017bc40ad6846758616ad2a9b197054,
title = "Disseminated Enteroviral Infection Associated with Obinutuzumab",
abstract = "Two cases of disseminated enteroviral infection occurred in patients who received the CD20 monoclonal antibody obinutuzumab. Clinical features included hepatitis, edema, and a dermatomyositis-like syndrome. These manifestations may be unfamiliar to clinicians and are possibly responsive to intravenous immunoglobulin. Clinicians should remain vigilant for enteroviral infections in patients receiving obinutuzumab.",
author = "Claire Dendle and Michael Gilbertson and Tony Korman and Vera Golder and Morand, {Eric Francis} and Stephen Opat",
year = "2015",
doi = "10.3201/eid2109.150104",
language = "English",
volume = "21",
pages = "1661 -- 1663",
journal = "Emerging infectious diseases",
issn = "1080-6040",
publisher = "Centers for Disease Control and Prevention",
number = "9",

}

TY - JOUR

T1 - Disseminated Enteroviral Infection Associated with Obinutuzumab

AU - Dendle, Claire

AU - Gilbertson, Michael

AU - Korman, Tony

AU - Golder, Vera

AU - Morand, Eric Francis

AU - Opat, Stephen

PY - 2015

Y1 - 2015

N2 - Two cases of disseminated enteroviral infection occurred in patients who received the CD20 monoclonal antibody obinutuzumab. Clinical features included hepatitis, edema, and a dermatomyositis-like syndrome. These manifestations may be unfamiliar to clinicians and are possibly responsive to intravenous immunoglobulin. Clinicians should remain vigilant for enteroviral infections in patients receiving obinutuzumab.

AB - Two cases of disseminated enteroviral infection occurred in patients who received the CD20 monoclonal antibody obinutuzumab. Clinical features included hepatitis, edema, and a dermatomyositis-like syndrome. These manifestations may be unfamiliar to clinicians and are possibly responsive to intravenous immunoglobulin. Clinicians should remain vigilant for enteroviral infections in patients receiving obinutuzumab.

UR - http://www.ncbi.nlm.nih.gov/pubmed/26291712

U2 - 10.3201/eid2109.150104

DO - 10.3201/eid2109.150104

M3 - Article

VL - 21

SP - 1661

EP - 1663

JO - Emerging infectious diseases

JF - Emerging infectious diseases

SN - 1080-6040

IS - 9

ER -